Keyword: Catalyst Pharmaceutical
Catalyst pinned down the FDA’s first approval for rare autoimmune disorder Lambert-Eaton myasthenic syndrome.
Catalyst Pharmaceuticals is having to tighten its belt and cut nearly a third of its staff in order to retain enough cash to undertake new studies for its key drug Firdapse.
Two months ago the FDA slapped a Refuse to File letter on Catalyst Pharmaceuticals’ rare disease drug Firdapse--and the woe keeps raining down as the U.S. regulator now wants the biotech to undertake more trials.
